Search

Your search keyword '"Recalde, Martina"' showing total 48 results
Start Over Author "Recalde, Martina"
48 results on '"Recalde, Martina"'

1. Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies

Author

Fontvieille, Emma, Viallon, Vivian, Recalde, Martina, Cordova, Reynalda, Jansana, Anna, Peruchet-Noray, Laia, Lennon, Hannah, Heath, Alicia K., Aune, Dagfinn, Christakoudi, Sofia, Katzke, Verena, Kaaks, Rudolf, Inan-Eroglu, Elif, Schulze, Matthias B., Mellemkjær, Lene, Tjønneland, Anne, Overvad, Kim, Farràs, Marta, Petrova, Dafina, Amiano, Pilar, Chirlaque, María-Dolores, Moreno-Iribas, Conchi, Tin Tin, Sandar, Masala, Giovanna, Sieri, Sabina, Ricceri, Fulvio, Panico, Salvatore, May, Anne M., Monninkhof, Evelyn M., Weiderpass, Elisabete, Gunter, Marc J., Ferrari, Pietro, and Freisling, Heinz

Published
2023
Full Text
View/download PDF

3. Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

Author

Kostka, Kristin, Duarte-Salles, Talita, Prats-Uribe, Albert, Sena, Anthony G, Pistillo, Andrea, Khalid, Sara, Lai, Lana YH, Golozar, Asieh, Alshammari, Thamir M, Dawoud, Dalia M, Nyberg, Fredrik, Wilcox, Adam B, Andryc, Alan, Williams, Andrew, Ostropolets, Anna, Areia, Carlos, Jung, Chi Young, Harle, Christopher A, Reich, Christian G, Blacketer, Clair, Morales, Daniel R, Dorr, David A, Burn, Edward, Roel, Elena, Tan, Eng Hooi, Minty, Evan, DeFalco, Frank, de Maeztu, Gabriel, Lipori, Gigi, Alghoul, Hiba, Zhu, Hong, Thomas, Jason A, Bian, Jiang, Park, Jimyung, Roldán, Jordi Martínez, Posada, Jose D, Banda, Juan M, Horcajada, Juan P, Kohler, Julianna, Shah, Karishma, Natarajan, Karthik, Lynch, Kristine E, Liu, Li, Schilling, Lisa M, Recalde, Martina, Spotnitz, Matthew, Gong, Mengchun, Matheny, Michael E, Valveny, Neus, Weiskopf, Nicole G, Shah, Nigam, Alser, Osaid, Casajust, Paula, Park, Rae Woong, Schuff, Robert, Seager, Sarah, DuVall, Scott L, You, Seng Chan, Song, Seokyoung, Fernández-Bertolín, Sergio, Fortin, Stephen, Magoc, Tanja, Falconer, Thomas, Subbian, Vignesh, Huser, Vojtech, Ahmed, Waheed-Ul-Rahman, Carter, William, Guan, Yin, Galvan, Yankuic, He, Xing, Rijnbeek, Peter R, Hripcsak, George, Ryan, Patrick B, Suchard, Marc A, and Prieto-Alhambra, Daniel

Subjects
Clinical Research, Infectious Diseases, Prevention, 2.4 Surveillance and distribution, Aetiology, Good Health and Well Being, OHDSI, OMOP CDM, descriptive epidemiology, real world data, real world evidence, open science, Clinical Sciences, Public Health and Health Services
Abstract

PurposeRoutinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.Patients and methodsWe conducted a descriptive retrospective database study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub. We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services.ResultsWe aggregated over 22,000 unique characteristics describing patients with COVID-19. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts and are readily available online. Globally, we observed similarities in the USA and Europe: more women diagnosed than men but more men hospitalized than women, most diagnosed cases between 25 and 60 years of age versus most hospitalized cases between 60 and 80 years of age. South Korea differed with more women than men hospitalized. Common comorbidities included type 2 diabetes, hypertension, chronic kidney disease and heart disease. Common presenting symptoms were dyspnea, cough and fever. Symptom data availability was more common in hospitalized cohorts than diagnosed.ConclusionWe constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.

Published
2022

4. Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study

Author

Reyes, Carlen, Pistillo, Andrea, Fernández-Bertolín, Sergio, Recalde, Martina, Roel, Elena, Puente, Diana, Sena, Anthony G, Blacketer, Clair, Lai, Lana, Alshammari, Thamir M, Ahmed, Waheed-UI-Rahman, Alser, Osaid, Alghoul, Heba, Areia, Carlos, Dawoud, Dalia, Prats-Uribe, Albert, Valveny, Neus, de Maeztu, Gabriel, Redó, Luisa Sorlí, Roldan, Jordi Martinez, Montesinos, Inmaculada Lopez, Schilling, Lisa M, Golozar, Asieh, Reich, Christian, Posada, Jose D, Shah, Nigam, You, Seng Chan, Lynch, Kristine E, DuVall, Scott L, Matheny, Michael E, Nyberg, Fredrik, Ostropolets, Anna, Hripcsak, George, Rijnbeek, Peter R, Suchard, Marc A, Ryan, Patrick, Kostka, Kristin, and Duarte-Salles, Talita

Subjects
Clinical Research, Cardiovascular, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, COVID-19, COVID-19 Testing, Cohort Studies, Comorbidity, Female, Hospitalization, Humans, Hypertension, Middle Aged, Retrospective Studies, SARS-CoV-2, epidemiology, hypertension, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

ObjectiveTo characterise patients with and without prevalent hypertension and COVID-19 and to assess adverse outcomes in both inpatients and outpatients.Design and settingThis is a retrospective cohort study using 15 healthcare databases (primary and secondary electronic healthcare records, insurance and national claims data) from the USA, Europe and South Korea, standardised to the Observational Medical Outcomes Partnership common data model. Data were gathered from 1 March to 31 October 2020.ParticipantsTwo non-mutually exclusive cohorts were defined: (1) individuals diagnosed with COVID-19 (diagnosed cohort) and (2) individuals hospitalised with COVID-19 (hospitalised cohort), and stratified by hypertension status. Follow-up was from COVID-19 diagnosis/hospitalisation to death, end of the study period or 30 days.OutcomesDemographics, comorbidities and 30-day outcomes (hospitalisation and death for the 'diagnosed' cohort and adverse events and death for the 'hospitalised' cohort) were reported.ResultsWe identified 2 851 035 diagnosed and 563 708 hospitalised patients with COVID-19. Hypertension was more prevalent in the latter (ranging across databases from 17.4% (95% CI 17.2 to 17.6) to 61.4% (95% CI 61.0 to 61.8) and from 25.6% (95% CI 24.6 to 26.6) to 85.9% (95% CI 85.2 to 86.6)). Patients in both cohorts with hypertension were predominantly >50 years old and female. Patients with hypertension were frequently diagnosed with obesity, heart disease, dyslipidaemia and diabetes. Compared with patients without hypertension, patients with hypertension in the COVID-19 diagnosed cohort had more hospitalisations (ranging from 1.3% (95% CI 0.4 to 2.2) to 41.1% (95% CI 39.5 to 42.7) vs from 1.4% (95% CI 0.9 to 1.9) to 15.9% (95% CI 14.9 to 16.9)) and increased mortality (ranging from 0.3% (95% CI 0.1 to 0.5) to 18.5% (95% CI 15.7 to 21.3) vs from 0.2% (95% CI 0.2 to 0.2) to 11.8% (95% CI 10.8 to 12.8)). Patients in the COVID-19 hospitalised cohort with hypertension were more likely to have acute respiratory distress syndrome (ranging from 0.1% (95% CI 0.0 to 0.2) to 65.6% (95% CI 62.5 to 68.7) vs from 0.1% (95% CI 0.0 to 0.2) to 54.7% (95% CI 50.5 to 58.9)), arrhythmia (ranging from 0.5% (95% CI 0.3 to 0.7) to 45.8% (95% CI 42.6 to 49.0) vs from 0.4% (95% CI 0.3 to 0.5) to 36.8% (95% CI 32.7 to 40.9)) and increased mortality (ranging from 1.8% (95% CI 0.4 to 3.2) to 25.1% (95% CI 23.0 to 27.2) vs from 0.7% (95% CI 0.5 to 0.9) to 10.9% (95% CI 10.4 to 11.4)) than patients without hypertension.ConclusionsCOVID-19 patients with hypertension were more likely to suffer severe outcomes, hospitalisations and deaths compared with those without hypertension.

Published
2021

5. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries

Author

Tan, Eng Hooi, Sena, Anthony G, Prats-Uribe, Albert, You, Seng Chan, Ahmed, Waheed-Ul-Rahman, Kostka, Kristin, Reich, Christian, Duvall, Scott L, Lynch, Kristine E, Matheny, Michael E, Duarte-Salles, Talita, Bertolin, Sergio Fernandez, Hripcsak, George, Natarajan, Karthik, Falconer, Thomas, Spotnitz, Matthew, Ostropolets, Anna, Blacketer, Clair, Alshammari, Thamir M, Alghoul, Heba, Alser, Osaid, Lane, Jennifer CE, Dawoud, Dalia M, Shah, Karishma, Yang, Yue, Zhang, Lin, Areia, Carlos, Golozar, Asieh, Recalde, Martina, Casajust, Paula, Jonnagaddala, Jitendra, Subbian, Vignesh, Vizcaya, David, Lai, Lana YH, Nyberg, Fredrik, Morales, Daniel R, Posada, Jose D, Shah, Nigam H, Gong, Mengchun, Vivekanantham, Arani, Abend, Aaron, Minty, Evan P, Suchard, Marc, Rijnbeek, Peter, Ryan, Patrick B, and Prieto-Alhambra, Daniel

Subjects
Infectious Diseases, Lung, Emerging Infectious Diseases, Pneumonia & Influenza, Clinical Research, Influenza, Autoimmune Disease, Cardiovascular, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Autoimmune Diseases, COVID-19, Cohort Studies, Female, Hospitalization, Humans, Influenza, Human, Male, Middle Aged, Prevalence, Prognosis, Republic of Korea, SARS-CoV-2, Spain, United States, Young Adult, autoimmune condition, mortality, hospitalization, open science, Observational Health Data Sciences and Informatics, Observational Medical Outcomes Partnership, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectivePatients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.MethodsA multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization.ResultsWe studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).ConclusionCompared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.

Published
2021

6. Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and SpainCharacteristics of 300,000 COVID-19 Individuals with Cancer

Author

Roel, Elena, Pistillo, Andrea, Recalde, Martina, Sena, Anthony G, Fernández-Bertolín, Sergio, Aragón, Maria, Puente, Diana, Ahmed, Waheed-Ul-Rahman, Alghoul, Heba, Alser, Osaid, Alshammari, Thamir M, Areia, Carlos, Blacketer, Clair, Carter, William, Casajust, Paula, Culhane, Aedin C, Dawoud, Dalia, DeFalco, Frank, DuVall, Scott L, Falconer, Thomas, Golozar, Asieh, Gong, Mengchun, Hester, Laura, Hripcsak, George, Tan, Eng Hooi, Jeon, Hokyun, Jonnagaddala, Jitendra, Lai, Lana YH, Lynch, Kristine E, Matheny, Michael E, Morales, Daniel R, Natarajan, Karthik, Nyberg, Fredrik, Ostropolets, Anna, Posada, José D, Prats-Uribe, Albert, Reich, Christian G, Rivera, Donna R, Schilling, Lisa M, Soerjomataram, Isabelle, Shah, Karishma, Shah, Nigam H, Shen, Yang, Spotniz, Matthew, Subbian, Vignesh, Suchard, Marc A, Trama, Annalisa, Zhang, Lin, Zhang, Ying, Ryan, Patrick B, Prieto-Alhambra, Daniel, Kostka, Kristin, and Duarte-Salles, Talita

Subjects
Biomedical and Clinical Sciences, Health Services and Systems, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Patient Safety, Infectious Diseases, Rare Diseases, Hematology, Cancer, Urologic Diseases, Prevention, Clinical Research, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, COVID-19, Child, Cohort Studies, Comorbidity, Databases, Factual, Female, Hospitalization, Humans, Immunosuppression Therapy, Influenza, Human, Male, Middle Aged, Neoplasms, Outcome Assessment, Health Care, Pandemics, Prevalence, Risk Factors, SARS-CoV-2, Spain, United States, Young Adult, Medical and Health Sciences, Epidemiology, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundWe described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.MethodsWe conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.ResultsWe included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%-18% and 1%-14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events.ConclusionsPatients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent.ImpactThis study provides epidemiologic characteristics that can inform clinical care and etiologic studies.

Published
2021

7. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.

Author

Prats-Uribe, Albert, Sena, Anthony G, Lai, Lana Yin Hui, Ahmed, Waheed-Ul-Rahman, Alghoul, Heba, Alser, Osaid, Alshammari, Thamir M, Areia, Carlos, Carter, William, Casajust, Paula, Dawoud, Dalia, Golozar, Asieh, Jonnagaddala, Jitendra, Mehta, Paras P, Gong, Mengchun, Morales, Daniel R, Nyberg, Fredrik, Posada, Jose D, Recalde, Martina, Roel, Elena, Shah, Karishma, Shah, Nigam H, Schilling, Lisa M, Subbian, Vignesh, Vizcaya, David, Zhang, Lin, Zhang, Ying, Zhu, Hong, Liu, Li, Cho, Jaehyeong, Lynch, Kristine E, Matheny, Michael E, You, Seng Chan, Rijnbeek, Peter R, Hripcsak, George, Lane, Jennifer Ce, Burn, Edward, Reich, Christian, Suchard, Marc A, Duarte-Salles, Talita, Kostka, Kristin, Ryan, Patrick B, and Prieto-Alhambra, Daniel

Subjects
Humans, Ceftriaxone, Azithromycin, Ritonavir, Hydroxychloroquine, Fluoroquinolones, Adrenal Cortex Hormones, Enoxaparin, Vitamin D, Drug Combinations, Treatment Outcome, Chemotherapy, Adjuvant, Cohort Studies, Safety, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, Inpatients, United States, China, Spain, Female, Male, Young Adult, Republic of Korea, Electronic Health Records, Drug Repositioning, Lopinavir, Administrative Claims, Healthcare, COVID-19, SARS-CoV-2, Administrative Claims, Healthcare, and over, Chemotherapy, Adjuvant, Preschool, Newborn, General & Internal Medicine, Clinical Sciences, Public Health and Health Services
Abstract

ObjectiveTo investigate the use of repurposed and adjuvant drugs in patients admitted to hospital with covid-19 across three continents.DesignMultinational network cohort study.SettingHospital electronic health records from the United States, Spain, and China, and nationwide claims data from South Korea.Participants303 264 patients admitted to hospital with covid-19 from January 2020 to December 2020.Main outcome measuresPrescriptions or dispensations of any drug on or 30 days after the date of hospital admission for covid-19.ResultsOf the 303 264 patients included, 290 131 were from the US, 7599 from South Korea, 5230 from Spain, and 304 from China. 3455 drugs were identified. Common repurposed drugs were hydroxychloroquine (used in from

Published
2021

8. Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia.

Author

López‐Jiménez, Tomàs, Plana‐Ripoll, Oleguer, Duarte‐Salles, Talita, Recalde, Martina, Bennett, Matthew, Xavier‐Cos, Francesc, and Puente, Diana

Subjects
DISEASE risk factors, METABOLIC syndrome, DATABASES, CANCER diagnosis, WORLD health
Abstract

Background: Metabolic syndrome (MS) has emerged as a significant global health concern. The relationship between MS and the risk of cancer doesn't seem clear, whether examining by components or in combination. The objective of this study is to examine the relationship between MS, its components, and the overall risk of cancer, including the risk of 13 specific cancer types. Methods: We included 3,918,781 individuals aged 40 years or older sourced from the SIDIAP database between 2008 and 2017. Cox models were employed with MS components and their combinations. A subsample was created using a matched cohort (by age and sex). Incidence curves were computed to determine the time elapsed between the date of having 1–5 MS components and cancer incidence, compared to matched participants with no MS components, which showed that individuals who had one MS component experienced a greater incidence of cancer over 5 and 10 years than individuals with no MS, and the incidence rose with an increase in the number of MS components. Results: Individuals exposed to MS components were diagnosed with cancer earlier than those who were not exposed to them. In the Cox model, HDL (HR 1.46, 95% CI: 1.41–1.52) and Glycemia (HR 1.40, 95% CI: 1.37–1.44) were the individual combinations with the highest risk of overall cancer. In combinations with two components, the highest HR was HDL+Glycemia (HR 1.52, 95% CI: 1.45–1.59) and Glycemia+HBP (HR 1.48, 95% CI: 1.45–1.50). In combinations with three components, the highest HR was HDL+Glycemia+HBP (HR 1.58, 95% CI: 1.55–1.62). Conclusion: In summary, having one or more MS components raises the risk of developing at least 11 cancer types and these risk differ according to type of component included. Some sex differences are also observed. Our findings suggest that implementing prevention measures aimed at specific MS components may lower the risk of various cancer types. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Author

Recalde, Martina, Roel, Elena, Pistillo, Andrea, Sena, Anthony G., Prats-Uribe, Albert, Ahmed, Waheed-Ul-Rahman, Alghoul, Heba, Alshammari, Thamir M., Alser, Osaid, Areia, Carlos, Burn, Edward, Casajust, Paula, Dawoud, Dalia, DuVall, Scott L., Falconer, Thomas, Fernández-Bertolín, Sergio, Golozar, Asieh, Gong, Mengchun, Lai, Lana Yin Hui, Lane, Jennifer C. E., Lynch, Kristine E., Matheny, Michael E., Mehta, Paras P., Morales, Daniel R., Natarjan, Karthik, Nyberg, Fredrik, Posada, Jose D., Reich, Christian G., Rijnbeek, Peter R., Schilling, Lisa M., Shah, Karishma, Shah, Nigam H., Subbian, Vignesh, Zhang, Lin, Zhu, Hong, Ryan, Patrick, Prieto-Alhambra, Daniel, Kostka, Kristin, and Duarte-Salles, Talita

Published
2021
Full Text
View/download PDF

14. Transforming the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model and Its Use for COVID-19 Research

Author

Raventós, Berta, primary, Fernández-Bertolín, Sergio, additional, Aragón, María, additional, Voss, Erica A, additional, Blacketer, Clair, additional, Méndez-Boo, Leonardo, additional, Recalde, Martina, additional, Roel, Elena, additional, Pistillo, Andrea, additional, Reyes, Carlen, additional, van Sandijk, Sebastiaan, additional, Halvorsen, Lars, additional, Rijnbeek, Peter R, additional, Burn, Edward, additional, and Duarte-Salles, Talita, additional

Published
2023
Full Text
View/download PDF

16. Air pollution and green spaces in relation to breast cancer risk among pre and postmenopausal women: A mega cohort from Catalonia

Author

Terre-Torras, Isaura, primary, Recalde, Martina, additional, Díaz, Yesika, additional, de Bont, Jeroen, additional, Bennett, Matthew, additional, Aragón, María, additional, Cirach, Marta, additional, O'Callaghan-Gordo, Cristina, additional, Nieuwenhuijsen, Mark J., additional, and Duarte-Salles, Talita, additional

Published
2022
Full Text
View/download PDF

19. Association between metabolic syndrome and 13 types of cancer in Catalonia : A matched case-control study

Author

López-Jiménez, Tomàs, Duarte-Salles, Talita, Plana-Ripoll, Oleguer, Recalde, Martina, Cos Claramunt, Francesc Xavier, Puente, Diana, and Universitat Autònoma de Barcelona

Subjects
Male, Metabolic Syndrome, Multidisciplinary, Lung Neoplasms, Risk Factors, Spain, Case-Control Studies, Lymphoma, Non-Hodgkin, Humans, Breast Neoplasms, Female, Colorectal Neoplasms
Abstract

Background Metabolic syndrome (MS) is the simultaneous occurrence of a cluster of predefined cardiovascular risk factors. Although individual MS components are associated with increased risk of cancer, it is still unclear whether the association between MS and cancer differs from the association between individual MS components and cancer. The aim of this matched case-control study was to estimate the association of 13 types of cancer with (1) MS and (2) the diagnosis of 0, 1 or 2 individual MS components. Methods Cases included 183,248 patients ≥40 years from the SIDIAP database with incident cancer diagnosed between January 2008-December 2017. Each case was matched to four controls by inclusion date, sex and age. Adjusted conditional logistic regression models were used to evaluate the association between MS and cancer risk, comparing the effect of global MS versus having one or two individual components of MS. Results MS was associated with an increased risk of the following cancers: colorectal (OR: 1.28, 95%CI: 1.23–1.32), liver (OR: 1.93, 95%CI: 1.74–2.14), pancreas (OR: 1.79, 95%CI: 1.63–1.98), post-menopausal breast (OR: 1.10, 95%CI: 1.06–1.15), pre-menopausal endometrial (OR: 2.14, 95%CI: 1.74–2.65), post-menopausal endometrial (OR: 2.46, 95%CI: 2.20–2.74), bladder (OR: 1.41, 95%CI: 1.34–1.48), kidney (OR: 1.84, 95%CI: 1.69–2.00), non-Hodgkin lymphoma (OR: 1.23, 95%CI: 1.10–1.38), leukaemia (OR: 1.42, 95%CI: 1.31–1.54), lung (OR: 1.11, 95%CI: 1.05–1.16) and thyroid (OR: 1.71, 95%CI: 1.50–1.95). Except for prostate, pre-menopause breast cancer and Hodgkin and non-Hodgkin lymphoma, MS is associated with a higher risk of cancer than 1 or 2 individual MS components. Estimates were significantly higher in men than in women for colorectal and lung cancer, and in smokers than in non-smokers for lung cancer. Conclusion MS is associated with a higher risk of developing 11 types of common cancer, with a positive correlation between number of MS components and risk of cancer.

Published
2022

20. Adiposity, cardiometabolic conditions, and cancer risk : Evidence from electronic health records in Catalonia

Author

Recalde, Martina, Duarte Salles, Talita, Freisling, Heinz, Castells, Xavier, Duarte-Salles, Talita, and Duarte Salles, Talita, 1985

Subjects
Cáncer, Índice de masa corporal, Càncer, Ciències de la Salut, Índex de massa corporal, Body mass index, Cancer
Abstract

El càncer és una de les principals causes de morbiditat i mortalitat en el món i a Espanya. L’Índex de massa corporal (IMC), l’indicador més comú d’adipositat general, ha estat associat amb el risc de diversos tipus de càncer. En l’àmbit de l’epidemiologia del càncer, l’ús de bases de dades d’històries clíniques electròniques (EHR, de l’anglès) recollides de manera rutinària ha guanyat importància en les últimes dècades i podria ser útil per a omplir llacunes en la recerca de l’obesitat i el càncer. El principal objectiu d’aquesta Tesi era investigar l’associació entre l’adipositat i el risc de càncer, així com el rol de les condicions cardiometabòliques en aquesta relació. Prèviament, vam avaluar l’adequació d’una gran base de dades de EHR de Catalunya, Espanya, per a la recerca, i més específicament, per a la recerca relacionada amb el càncer. En aquesta Tesi, proporcionem una extensa caracterització de la base de dades del Sistema d’Informació per al Desenvolupament de la Recerca en Atenció Primària (SIDIAP), validem 25 tipus de casos de càncers incidents en el SIDIAP utilitzant registres regionals de càncer com a criteri de referència i investiguem l’associació entre l’adipositat i el risc de 26 tipus de càncer tenint en compte possibles associacions no lineals, diferents indicadors d’adipositat, i factors a escala individual com l’hàbit tabàquic i condicions cardiometabòliques incidents. Les troballes d’aquesta Tesi mostren que el SIDIAP és una base de dades adequada per a realitzar recerca relacionada amb la salut i el càncer. El SIDIAP inclou el 76% dels diagnòstics de càncer dels registres de càncer poblacionals de Catalunya, però també inclou un considerable nombre de casos que no figuren en els registres. A més, l’adipositat s’associa amb un major risc de diversos tipus de càncer. Confirmem associacions prèviament trobades en estudis focalitzats en mesures basals d’IMC i proporcionem nova evidència, mostrant que una exposició major i més llarga a l’adipositat incrementa el risc de quatre càncers hematològics, així com de càncers de cap i coll i de bufeta (únicament entre persones que no han estat mai fumadores). L’associació entre adipositat i càncer és similar en individus sense condicions cardiometabòliques i en aquells amb hipertensió i malaltia cardiovascular incidents, però l’associació es menor en persones amb diabetis de tipus 2. Finalment, hem observat que l’IMC i el perímetre de cintura són estimadors similars del risc de càncer associat amb l’adipositat en l’àmbit poblacional. Les troballes d’aquesta Tesi reforcen la necessitat d’estratègies de salut pública per a reduir i prevenir el sobrepès i l’obesitat. Les troballes també ressalten la utilitat de les EHR per a realitzar recerca en salut i proporcionar evidència per a l’acció en l’àmbit de la salut pública. El cáncer es una de las principales causas de morbilidad y mortalidad en el mundo y en España. El Índice de masa corporal (IMC), el indicador más común de adiposidad general, ha sido asociado con el riesgo de varios tipos de cáncer. El uso de bases de datos de historias clínicas electrónicas (EHR, del inglés) recolectadas de forma rutinaria se ha vuelto más común en las últimas décadas en la epidemiología del cáncer y podría ser útil para colmar lagunas en la literatura de la obesidad y el cáncer. El principal objetivo de esta Tesis era investigar la asociación entre la adiposidad y el riesgo de cáncer, así como también el rol de condiciones cardiometabólicas en esta relación. Como paso previo, teníamos el objetivo de evaluar la adecuación de una gran base de datos de EHR de Cataluña, España para la investigación, y más específicamente, para la investigación relacionada con el cáncer. En esta Tesis, proporcionamos una extensa caracterización de la base de datos del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP), validamos 25 tipos de casos de cánceres incidentes en el SIDIAP utilizando registros regionales de cáncer como criterio de referencia e investigamos la asociación entre la adiposidad y el riesgo de 26 tipos de cáncer teniendo en cuenta posibles asociaciones no lineales, diferentes indicadores de adiposidad, y factores a nivel individual como el hábito tabáquico y condiciones cardiometabólicas incidentes. Los hallazgos de esta Tesis revelaron que el SIDIAP es una base de datos adecuada para realizar investigación relacionada con la salud y el cáncer. El SIDIAP incluye el 76% de los diagnósticos de cáncer de los registros de cáncer poblacionales de Cataluña, pero incluye un considerable número de casos que no figuran en los registros. Además, la adiposidad se asocia con un mayor riesgo de diversos tipos de cáncer. Confirmamos asociaciones previamente encontradas en estudios focalizados en medidas basales de IMC y proporcionamos novedosa evidencia de que una mayor y más larga exposición a la adiposidad incrementa el riesgo de cuatro cánceres hematológicos asi como del cáncer de cabeza y cuello y de véjiga [únicamente entre los nunca fumadores]). La asociación entre adiposidad y cáncer es similar en individuos sin condiciones cardiometabólicas y en aquellos con hipertensión y enfermedad cardiovascular incidentes, pero la asociación se atenúa en personas con diabetes de tipo 2. Tanto el IMC como el perímetro de cintura resultan en estimadores de riesgo de cáncer asociado con la adiposidad similares a nivel poblacional. Los hallazgos de esta Tesis refuerzan la necesidad de estrategias de salud pública para reducir y prevenir el sobrepeso y la obesidad. Los hallazgos también resaltan la utilidad de las EHR para realizar investigación en salud y proporcionar evidencia para la acción en el ámbito de la salud pública. Cancer is one of the leading causes of morbidity and mortality worldwide and in Spain. Body mass index (BMI), the most common indicator of general adiposity, has been associated with the risk of several cancer types. The use of databases of routinely collected electronic health records (EHR) has become more common in cancer epidemiology over the past decades and could be useful to fill in gaps in the adiposity-cancer literature. The main aim of this Thesis was to investigate the association between adiposity and cancer risk as well as the role of cardiometabolic conditions in this relationship. As a prior step, we aimed to evaluate the suitability of a large EHR database from Catalonia, Spain for research and, more specifically, for cancer-related research. In this Thesis, we provide an extensive characterization of the Information System for Research in Primary Care (SIDIAP) database, we validate 25 types of incident cancer cases in the SIDIAP using regional cancer registries as the gold standard and we investigate the association between adiposity and the risk of 26 types of cancer accounting for potential non-linearity, different adiposity indicators, and individual-level factors such as smoking status and incident cardiometabolic conditions. The findings of this Thesis revealed that SIDIAP is a suitable database to conduct health- and cancer-related research. SIDIAP includes 76% of the cancer diagnoses in the population-based cancer registries of Catalonia but includes a considerable number of cases that are not in the registries. Furthermore, adiposity is associated with an increased risk of several cancer types. We confirmed associations previously reported in studies focusing on baseline BMI and we provide novel evidence that higher and longer exposure to adiposity increases the risk of four hematological as well as head and neck and bladder (among never smokers) cancers. The BMI- cancer association is similar among individuals free of cardiometabolic conditions and those with incident hypertension and/or cardiovascular disease but it is attenuated among individuals with type 2 diabetes mellitus. BMI and waist circumference result in comparable estimates of cancer risk associated with adiposity at a population level. The findings of this Thesis reinforce the need for public health strategies to reduce and prevent overweight and obesity. The findings also highlight the usefulness of EHRs for conducting health-related research and providing evidence for public health action. Universitat Autònoma de Barcelona. Programa de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública

Published
2022

22. Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

Author

Kostka, Kristin, primary, Duarte-Salles, Talita, additional, Prats-Uribe, Albert, additional, Sena, Anthony G, additional, Pistillo, Andrea, additional, Khalid, Sara, additional, Lai, Lana YH, additional, Golozar, Asieh, additional, Alshammari, Thamir M, additional, Dawoud, Dalia M, additional, Nyberg, Fredrik, additional, Wilcox, Adam B, additional, Andryc, Alan, additional, Williams, Andrew, additional, Ostropolets, Anna, additional, Areia, Carlos, additional, Jung, Chi Young, additional, Harle, Christopher A, additional, Reich, Christian G, additional, Blacketer, Clair, additional, Morales, Daniel R, additional, Dorr, David A, additional, Burn, Edward, additional, Roel, Elena, additional, Tan, Eng Hooi, additional, Minty, Evan, additional, DeFalco, Frank, additional, de Maeztu, Gabriel, additional, Lipori, Gigi, additional, Alghoul, Heba, additional, Zhu, Hong, additional, Thomas, Jason A, additional, Bian, Jiang, additional, Park, Jimyung, additional, Martínez Roldán, Jordi, additional, Posada, Jose D, additional, Banda, Juan M, additional, Horcajada, Juan P, additional, Kohler, Julianna, additional, Shah, Karishma, additional, Natarajan, Karthik, additional, Lynch, Kristine E, additional, Liu, Li, additional, Schilling, Lisa M, additional, Recalde, Martina, additional, Spotnitz, Matthew, additional, Gong, Mengchun, additional, Matheny, Michael E, additional, Valveny, Neus, additional, Weiskopf, Nicole G, additional, Shah, Nigam, additional, Alser, Osaid, additional, Casajust, Paula, additional, Park, Rae Woong, additional, Schuff, Robert, additional, Seager, Sarah, additional, DuVall, Scott L, additional, You, Seng Chan, additional, Song, Seokyoung, additional, Fernández-Bertolín, Sergio, additional, Fortin, Stephen, additional, Magoc, Tanja, additional, Falconer, Thomas, additional, Subbian, Vignesh, additional, Huser, Vojtech, additional, Ahmed, Waheed-Ul-Rahman, additional, Carter, William, additional, Guan, Yin, additional, Galvan, Yankuic, additional, He, Xing, additional, Rijnbeek, Peter R, additional, Hripcsak, George, additional, Ryan, Patrick B, additional, Suchard, Marc A, additional, and Prieto-Alhambra, Daniel, additional

Published
2022
Full Text
View/download PDF

23. Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Author

Morales, Daniel R., primary, Ostropolets, Anna, additional, Lai, Lana, additional, Sena, Anthony, additional, Duvall, Scott, additional, Suchard, Marc, additional, Verhamme, Katia, additional, Rjinbeek, Peter, additional, Posada, Joe, additional, Ahmed, Waheed, additional, Alshammary, Thamer, additional, Alghoul, Heba, additional, Alser, Osaid, additional, Areia, Carlos, additional, Blacketer, Clair, additional, Burn, Edward, additional, Casajust, Paula, additional, You, Seng Chan, additional, Dawoud, Dalia, additional, Golozar, Asieh, additional, Gong, Menchung, additional, Jonnagaddala, Jitendra, additional, Lynch, Kristine, additional, Matheny, Michael, additional, Minty, Evan, additional, Nyberg, Fredrik, additional, Uribe, Albert, additional, Recalde, Martina, additional, Reich, Christian, additional, Scheumie, Martijn, additional, Shah, Karishma, additional, Shah, Nigam, additional, Schilling, Lisa, additional, Vizcaya, David, additional, Zhang, Lin, additional, Hripcsak, George, additional, Ryan, Patrick, additional, Prieto-Alhambra, Daniel, additional, Durate-Salles, Talita, additional, and Kostka, Kristin, additional

Published
2022
Full Text
View/download PDF

25. Establishing and characterising large COVID-19 cohorts after mapping the Information System for Research in Primary Care in Catalonia to the OMOP Common Data Model

Author

Burn, Edward, primary, Fernández-Bertolín, Sergio, additional, Voss, Erica A, additional, Blacketer, Clair, additional, Aragón, Maria, additional, Recalde, Martina, additional, Roel, Elena, additional, Pistillo, Andrea, additional, Raventós, Berta, additional, Reyes, Carlen, additional, van Sandijk, Sebastiaan, additional, Halvorsen, Lars, additional, Rijnbeek, Peter R, additional, and Duarte-Salles, Talita, additional

Published
2021
Full Text
View/download PDF

26. Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population‐based multistate cohort study including 4 618 377 adults in Catalonia, Spain

Author

Roel, Elena, primary, Pistillo, Andrea, additional, Recalde, Martina, additional, Fernández‐Bertolín, Sergio, additional, Aragón, María, additional, Soerjomataram, Isabelle, additional, Jenab, Mazda, additional, Puente, Diana, additional, Prieto‐Alhambra, Daniel, additional, Burn, Edward, additional, and Duarte‐Salles, Talita, additional

Published
2021
Full Text
View/download PDF

27. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience

Author

Duarte-Salles, Talita, primary, Vizcaya, David, additional, Pistillo, Andrea, additional, Casajust, Paula, additional, Sena, Anthony G., additional, Lai, Lana Yin Hui, additional, Prats-Uribe, Albert, additional, Ahmed, Waheed-Ul-Rahman, additional, Alshammari, Thamir M., additional, Alghoul, Heba, additional, Alser, Osaid, additional, Burn, Edward, additional, You, Seng Chan, additional, Areia, Carlos, additional, Blacketer, Clair, additional, DuVall, Scott, additional, Falconer, Thomas, additional, Fernandez-Bertolin, Sergio, additional, Fortin, Stephen, additional, Golozar, Asieh, additional, Gong, Mengchun, additional, Tan, Eng Hooi, additional, Huser, Vojtech, additional, Iveli, Pablo, additional, Morales, Daniel R., additional, Nyberg, Fredrik, additional, Posada, Jose D., additional, Recalde, Martina, additional, Roel, Elena, additional, Schilling, Lisa M., additional, Shah, Nigam H., additional, Shah, Karishma, additional, Suchard, Marc A., additional, Zhang, Lin, additional, Zhang, Ying, additional, Williams, Andrew E., additional, Reich, Christian G., additional, Hripcsak, George, additional, Rijnbeek, Peter, additional, Ryan, Patrick, additional, Kostka, Kristin, additional, and Prieto-Alhambra, Daniel, additional

Published
2021
Full Text
View/download PDF

29. Additional file 1 of Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain

Author

Recalde, Martina, Davila-Batista, Veronica, Yesika Díaz, Leitzmann, Michael, Romieu, Isabelle, Freisling, Heinz, and Duarte-Salles, Talita

Abstract

Additional file 1: Appendix 1. definition of menopause and use of hormonal replacement therapy variables. Appendix 2. STROBE Statement-Checklist. Table S1. diagnostic codes used to define cancer cases. Table S2. characteristics of individuals with and without a BMI recorded. Table S3. BMI-cancer risk associations: results of the basic adjustment models. Table S4. P for non-linearity in WC-cancer risk associations. Table S5. A wide range of sensitivity analyses of BMI-cancer risk associations. Table S6. Sensitivity analyses of BMI-cancer risk associations using cancer registry data to confirm SIDIAP cases. Table S7. Sensitivity analyses of BMI-cancer risk associations excluding subgroups of participants. Table S8. Sensitivity analyses of BMI-cancer risk associations for women only cancers. Table S9. Sensitivity analysis including results of BMI/height/weight-cancer risk associations. Table S10. Sensitivity analysis of BMI/WC-cancer risk associations including additional adjustment for height. Table S11. Comparison of BMI information recorded in the SIDIAP and other studies’ data. Table S12. BMI-cancer risk associations stratified by sex. Figure 1. Directed Acyclic Graph that guided our decisions in the control for confounding. Figure 2. Sensitivity analysis of BMI/WC-cancer risk associations, including mutual adjustment using residuals of BMI and WC.

Published
2021
Full Text
View/download PDF

30. Cancer and the risk of COVID-19 diagnosis, hospitalisation, and death: a population-based multi-state cohort study including 4,618,377 adults in Catalonia, Spain

Author

Roel, Elena, primary, Pistillo, Andrea, additional, Recalde, Martina, additional, Fernández-Bertolín, Sergio, additional, Aragón, María, additional, Soerjomataram, Isabelle, additional, Jenab, Mazda, additional, Puente, Diana, additional, Prieto-Alhambra, Daniel, additional, Burn, Edward, additional, and Duarte-Salles, Talita, additional

Published
2021
Full Text
View/download PDF

31. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study

Author

Prats-Uribe, Albert, primary, Sena, Anthony G, additional, Lai, Lana Yin Hui, additional, Ahmed, Waheed-Ul-Rahman, additional, Alghoul, Heba, additional, Alser, Osaid, additional, Alshammari, Thamir M, additional, Areia, Carlos, additional, Carter, William, additional, Casajust, Paula, additional, Dawoud, Dalia, additional, Golozar, Asieh, additional, Jonnagaddala, Jitendra, additional, Mehta, Paras P, additional, Gong, Mengchun, additional, Morales, Daniel R, additional, Nyberg, Fredrik, additional, Posada, Jose D, additional, Recalde, Martina, additional, Roel, Elena, additional, Shah, Karishma, additional, Shah, Nigam H, additional, Schilling, Lisa M, additional, Subbian, Vignesh, additional, Vizcaya, David, additional, Zhang, Lin, additional, Zhang, Ying, additional, Zhu, Hong, additional, Liu, Li, additional, Cho, Jaehyeong, additional, Lynch, Kristine E, additional, Matheny, Michael E, additional, You, Seng Chan, additional, Rijnbeek, Peter R, additional, Hripcsak, George, additional, Lane, Jennifer CE, additional, Burn, Edward, additional, Reich, Christian, additional, Suchard, Marc A, additional, Duarte-Salles, Talita, additional, Kostka, Kristin, additional, Ryan, Patrick B, additional, and Prieto-Alhambra, Daniel, additional

Published
2021
Full Text
View/download PDF

32. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

Author

Prieto-Alhambra, Daniel, primary, Kostka, Kristin, additional, Duarte-Salles, Talita, additional, Prats-Uribe, Albert, additional, Sena, Anthony, additional, Pistillo, Andrea, additional, Khalid, Sara, additional, Lai, Lana, additional, Golozar, Asieh, additional, Alshammari, Thamir M, additional, Dawoud, Dalia, additional, Nyberg, Fredrik, additional, Wilcox, Adam, additional, Andryc, Alan, additional, Williams, Andrew, additional, Ostropolets, Anna, additional, Areia, Carlos, additional, Jung, Chi Young, additional, Harle, Christopher, additional, Reich, Christian, additional, Blacketer, Clair, additional, Morales, Daniel, additional, Dorr, David A., additional, Burn, Edward, additional, Roel, Elena, additional, Tan, Eng Hooi, additional, Minty, Evan, additional, DeFalco, Frank, additional, de Maeztu, Gabriel, additional, Lipori, Gigi, additional, Alghoul, Heba, additional, Zhu, Hong, additional, Thomas, Jason, additional, Bian, Jiang, additional, Park, Jimyung, additional, Roldán, Jordi Martínez, additional, Posada, Jose, additional, Banda, Juan M, additional, Horcajada, Juan P, additional, Kohler, Julianna, additional, Shah, Karishma, additional, Natarajan, Karthik, additional, Lynch, Kristine, additional, Liu, Li, additional, Schilling, Lisa, additional, Recalde, Martina, additional, Spotnitz, Matthew, additional, Gong, Mengchun, additional, Matheny, Michael, additional, Valveny, Neus, additional, Weiskopf, Nicole, additional, Shah, Nigam, additional, Alser, Osaid, additional, Casajust, Paula, additional, Park, Rae Woong, additional, Schuff, Robert, additional, Seager, Sarah, additional, DuVall, Scott, additional, You, Seng Chan, additional, Song, Seokyoung, additional, Fernández-Bertolín, Sergio, additional, Fortin, Stephen, additional, Magoc, Tanja, additional, Falconer, Thomas, additional, Subbian, Vignesh, additional, Huser, Vojtech, additional, Ahmed, Waheed-Ul-Rahman, additional, Carter, William, additional, Guan, Yin, additional, Galvan, Yankuic, additional, He, Xing, additional, Rijnbeek, Peter, additional, Hripcsak, George, additional, Ryan, Patrick, additional, and Suchard, Marc, additional

Published
2021
Full Text
View/download PDF

33. Body mass index and risk of COVID-19 diagnosis, hospitalisation, and death: a population-based multi-state cohort analysis including 2,524,926 people in Catalonia, Spain

Author

Recalde, Martina, primary, Pistillo, Andrea, additional, Fernandez-Bertolin, Sergio, additional, Roel, Elena, additional, Aragon, Maria, additional, Freisling, Heinz, additional, Prieto-Alhambra, Daniel, additional, Burn, Edward, additional, and Duarte-Salles, Talita, additional

Published
2020
Full Text
View/download PDF

34. Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States

Author

Burn, Edward, primary, Sena, Anthony G., additional, Prats-Uribe, Albert, additional, Spotnitz, Matthew, additional, DuVall, Scott, additional, Lynch, Kristine E., additional, Matheny, Michael E., additional, Nyberg, Fredrik, additional, Ahmed, Waheed-Ul-Rahman, additional, Alser, Osaid, additional, Alghoul, Heba, additional, Alshammari, Thamir, additional, Zhang, Lin, additional, Casajust, Paula, additional, Areia, Carlos, additional, Shah, Karishma, additional, Reich, Christian, additional, Blacketer, Clair, additional, Andryc, Alan, additional, Fortin, Stephen, additional, Natarajan, Karthik, additional, Gong, Mengchun, additional, Golozar, Asieh, additional, Morales, Daniel, additional, Rijnbeek, Peter, additional, Subbian, Vignesh, additional, Roel, Elena, additional, Recalde, Martina, additional, Lane, Jennifer C.E., additional, Vizcaya, David, additional, Posada, Jose D., additional, Shah, Nigam H., additional, Jonnagaddala, Jitendra, additional, Lai, Lana Yin Hui, additional, Avilés-Jurado, Francesc Xavier, additional, Hripcsak, George, additional, Suchard, Marc A., additional, Ranzani, Otavio T., additional, Ryan, Patrick, additional, Prieto-Alhambra, Daniel, additional, Kostka, Kristin, additional, and Duarte-Salles, Talita, additional

Published
2020
Full Text
View/download PDF

35. Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study

Author

Duarte-Salles, Talita, primary, Vizcaya, David, additional, Pistillo, Andrea, additional, Casajust, Paula, additional, Sena, Anthony G., additional, Lai, Lana Yin Hui, additional, Prats-Uribe, Albert, additional, Ahmed, Waheed-Ul-Rahman, additional, Alshammari, Thamir M, additional, Alghoul, Heba, additional, Alser, Osaid, additional, Burn, Edward, additional, You, Seng Chan, additional, Areia, Carlos, additional, Blacketer, Clair, additional, DuVall, Scott, additional, Falconer, Thomas, additional, Fernandez-Bertolin, Sergio, additional, Fortin, Stephen, additional, Golozar, Asieh, additional, Gong, Mengchun, additional, Tan, Eng Hooi, additional, Huser, Vojtech, additional, Iveli, Pablo, additional, Morales, Daniel R., additional, Nyberg, Fredrik, additional, Posada, Jose D., additional, Recalde, Martina, additional, Roel, Elena, additional, Schilling, Lisa M., additional, Shah, Nigam H., additional, Shah, Karishma, additional, Suchard, Marc A., additional, Zhang, Lin, additional, Zhang, Ying, additional, Williams, Andrew E., additional, Reich, Christian G., additional, Hripcsak, George, additional, Rijnbeek, Peter, additional, Ryan, Patrick, additional, Kostka, Kristin, additional, and Prieto-Alhambra, Daniel, additional

Published
2020
Full Text
View/download PDF

36. Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States

Author

Golozar, Asieh, primary, Lai, Lana YH, additional, Sena, Anthony G., additional, Vizcaya, David, additional, Schilling, Lisa M., additional, Huser, Vojtech, additional, Nyberg, Fredrik, additional, Duvall, Scott L., additional, Morales, Daniel R., additional, Alshammari, Thamir M, additional, Abedtash, Hamed, additional, Ahmed, Waheed-Ul-Rahman, additional, Alser, Osaid, additional, Alghoul, Heba, additional, Zhang, Ying, additional, Gong, Mengchun, additional, Guan, Yin, additional, Areia, Carlos, additional, Jonnagaddala, Jitendra, additional, Shah, Karishma, additional, Lane, Jennifer C.E., additional, Prats-Uribe, Albert, additional, Posada, Jose D., additional, Shah, Nigam H., additional, Subbian, Vignesh, additional, Zhang, Lin, additional, Fernandes Abrahão, Maria Tereza, additional, Rijnbeek, Peter R., additional, You, Seng Chan, additional, Casajust, Paula, additional, Roel, Elena, additional, Recalde, Martina, additional, Fernández-Bertolín, Sergio, additional, Andryc, Alan, additional, Thomas, Jason A., additional, Wilcox, Adam B., additional, Fortin, Stephen, additional, Blacketer, Clair, additional, DeFalco, Frank, additional, Natarajan, Karthik, additional, Falconer, Thomas, additional, Spotnitz, Matthew, additional, Ostropolets, Anna, additional, Hripcsak, George, additional, Suchard, Marc, additional, Lynch, Kristine E., additional, Matheny, Michael E., additional, Williams, Andrew, additional, Reich, Christian, additional, Duarte-Salles, Talita, additional, Kostka, Kristin, additional, Ryan, Patrick B., additional, and Prieto-Alhambra, Daniel, additional

Published
2020
Full Text
View/download PDF

37. “Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis”

Author

Lai, Lana Yin Hui, primary, Golozar, Asieh, additional, Sena, Anthony, additional, Margulis, Andrea V., additional, Haro, Nuria, additional, Casajust, Paula, additional, Valveny, Neus, additional, Prats-Uribe, Albert, additional, Minty, Evan P., additional, Ahmed, Waheed-Ul-Rahman, additional, Alshammari, Thamir M, additional, Morales, Daniel R., additional, Alghoul, Heba, additional, Alser, Osaid, additional, Dawoud, Dalia, additional, Zhang, Lin, additional, Posada, Jose D., additional, Shah, Nigam H., additional, Blacketer, Clair, additional, Areia, Carlos, additional, Subbian, Vignesh, additional, Nyberg, Fredrik, additional, Lane, Jennifer C E, additional, Suchard, Marc A, additional, Gong, Mengchun, additional, Recalde, Martina, additional, Jonnagaddala, Jitendra, additional, Shah, Karishma, additional, Roel, Elena, additional, Vizcaya, David, additional, Fortin, Stephen, additional, Joanne Cheng, Ru-fong, additional, Reich, Christian, additional, Hripcsak, George, additional, Rijnbeek, Peter, additional, Ryan, Patrick, additional, Kostka, Kristin, additional, Duarte-Salles, Talita, additional, and Prieto-Alhambra, Daniel, additional

Published
2020
Full Text
View/download PDF

38. Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population‐based multistate cohort study including 4 618 377 adults in Catalonia, Spain.

Author

Roel, Elena, Pistillo, Andrea, Recalde, Martina, Fernández‐Bertolín, Sergio, Aragón, María, Soerjomataram, Isabelle, Jenab, Mazda, Puente, Diana, Prieto‐Alhambra, Daniel, Burn, Edward, and Duarte‐Salles, Talita

Subjects
SKIN cancer, COVID-19, DIAGNOSIS, DISEASE risk factors, COVID-19 pandemic, ELECTRONIC health records
Abstract

The relationship between cancer and coronavirus disease 2019 (COVID‐19) infection and severity remains poorly understood. We conducted a population‐based cohort study between 1 March and 6 May 2020 describing the associations between cancer and risk of COVID‐19 diagnosis, hospitalisation and COVID‐19‐related death. Data were obtained from the Information System for Research in Primary Care (SIDIAP) database, including primary care electronic health records from ~80% of the population in Catalonia, Spain. Cancer was defined as any primary invasive malignancy excluding non‐melanoma skin cancer. We estimated adjusted hazard ratios (aHRs) for the risk of COVID‐19 (outpatient) clinical diagnosis, hospitalisation (with or without a prior COVID‐19 diagnosis) and COVID‐19‐related death using Cox proportional hazard regressions. Models were estimated for the overall cancer population and by years since cancer diagnosis (<1 year, 1‐5 years and ≥5 years), sex, age and cancer type; and adjusted for age, sex, smoking status, deprivation and comorbidities. We included 4 618 377 adults, of which 260 667 (5.6%) had a history of cancer. A total of 98 951 individuals (5.5% with cancer) were diagnosed, and 6355 (16.4% with cancer) were directly hospitalised with COVID‐19. Of those diagnosed, 6851 were subsequently hospitalised (10.7% with cancer), and 3227 died without being hospitalised (18.5% with cancer). Among those hospitalised, 1963 (22.5% with cancer) died. Cancer was associated with an increased risk of COVID‐19 diagnosis (aHR: 1.08; 95% confidence interval [1.05‐1.11]), direct COVID‐19 hospitalisation (1.33 [1.24‐1.43]) and death following hospitalisation (1.12 [1.01‐1.25]). These associations were stronger for patients recently diagnosed with cancer, aged <70 years, and with haematological cancers. These patients should be prioritised in COVID‐19 vaccination campaigns and continued non‐pharmaceutical interventions. What's new? Studies addressing associations between cancer and severity of coronavirus disease 2019 (COVID‐19) have focused primarily on hospitalized patients. Findings have been inconsistent, however, owing to varying cancer criteria, lack of representative samples, and other factors. Here, the natural history of COVID‐19 in cancer patients during the first wave of the pandemic in 2020 in Spain was investigated in a large, representative cohort with a heterogenous cancer population. Patients with cancer were at increased risk of severe COVID‐19. Risk was notably high among those over age 70 and those with recent cancer diagnosis, hematological cancer, or lung and bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Heterogeneity and temporal variation in the management of COVID-19: a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America

Author

Prats-Uribe, Albert, primary, Sena, Anthony G., additional, Hui Lai, Lana Yin, additional, Ahmed, Waheed-Ul-Rahman, additional, Alghoul, Heba, additional, Alser, Osaid, additional, Alshammari, Thamir M, additional, Areia, Carlos, additional, Carter, William, additional, Casajust, Paula, additional, Dawoud, Dalia, additional, Golozar, Asieh, additional, Jonnagaddala, Jitendra, additional, Mehta, Paras P., additional, Gong, Mengchun, additional, Morales, Daniel R., additional, Nyberg, Fredrik, additional, Posada, Jose D., additional, Recalde, Martina, additional, Roel, Elena, additional, Shah, Karishma, additional, H. Shah, Nigam, additional, Schilling, Lisa M., additional, Subbian, Vignesh, additional, Vizcaya, David, additional, Williams, Andrew, additional, Zhang, Lin, additional, Zhang, Ying, additional, Zhu, Hong, additional, Liu, Li, additional, Rijnbeek, Peter, additional, Hripcsak, George, additional, Lane, Jennifer CE, additional, Burn, Edward, additional, Reich, Christian, additional, Suchard, Marc A., additional, Duarte-Salles, Talita, additional, Kostka, Kristin, additional, Ryan, Patrick, additional, and Prieto-Alhambra, Daniel, additional

Published
2020
Full Text
View/download PDF

40. Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom

Author

Recalde, Martina, primary, Roel, Elena, additional, Pistillo, Andrea, additional, Sena, Anthony G., additional, Prats-Uribe, Albert, additional, Ahmed, Waheed-Ul-Rahman, additional, Alghoul, Heba, additional, Alshammari, Thamir M, additional, Alser, Osaid, additional, Areia, Carlos, additional, Burn, Edward, additional, Casajust, Paula, additional, Dawoud, Dalia, additional, DuVall, Scott L., additional, Falconer, Thomas, additional, Fernández-Bertolín, Sergio, additional, Golozar, Asieh, additional, Gong, Mengchun, additional, Lai, Lana Yin Hui, additional, Lane, Jennifer C.E., additional, Lynch, Kristine E., additional, Matheny, Michael E., additional, Mehta, Paras P, additional, Morales, Daniel R., additional, Natarjan, Karthik, additional, Nyberg, Fredrik, additional, Posada, Jose D., additional, Reich, Christian G., additional, Schilling, Lisa M., additional, Shah, Karishma, additional, Shah, Nigam H., additional, Subbian, Vignesh, additional, Zhang, Lin, additional, Zhu, Hong, additional, Ryan, Patrick, additional, Prieto-Alhambra, Daniel, additional, Kostka, Kristin, additional, and Duarte-Salles, Talita, additional

Published
2020
Full Text
View/download PDF

41. The natural history of symptomatic COVID-19 in Catalonia, Spain: a multi-state model including 109,367 outpatient diagnoses, 18,019 hospitalisations, and 5,585 COVID-19 deaths among 5,627,520 people

Author

Burn, Edward, primary, Tebé, Cristian, additional, Fernandez-Bertolin, Sergio, additional, Aragon, Maria, additional, Recalde, Martina, additional, Roel, Elena, additional, Prats-Uribe, Albert, additional, Prieto-Alhambra, Daniel, additional, and Duarte-Salles, Talita, additional

Published
2020
Full Text
View/download PDF

42. Validation Of Cancer Diagnoses In Electronic Health Records: Results From The Information System For Research In Primary Care (SIDIAP) In Northeast Spain

Author

Recalde, Martina, primary, Manzano-Salgado, Cyntia, additional, Díaz, Yesika, additional, Puente, Diana, additional, Garcia-Gil, Maria del Mar, additional, Marcos-Gragera, Rafael, additional, Ribes Puig, Josefa, additional, Galceran, Jaume, additional, Posso, Margarita, additional, Macià, Francesc, additional, and Duarte-Salles, Talita, additional

Published
2019
Full Text
View/download PDF

43. Los efectos de la ferocidad femenina en la tragedia griega : un enfoque psicoanalítico

Author

Bianchini, María Silvina and Edurne Recalde, Martina

Subjects
LITERATURA, MUJER, PSICOANÁLISIS
Abstract

Se propone comprender y caracterizar los efectos de la ferocidad femenina de los personajes de las tragedias griegas e identificar el modo en que cada uno de esos personajes femeninos elegidos encarnan un rasgo de la estructura definible como feroz. Tomando como eje la ferocidad femenina como exceso no elaborado que produce efectos de estrago en el cuerpo o en su relación con el partenaire, se aborda cómo la literatura ha realizado valiosos aportes al Psicoanálisis para pensar diferentes temáticas que hacen a la preocupación de los practicantes analistas, y se contextualiza el tiempo histórico y cultural en las que se desarrolla la tragedia griega como género literario. Se trabaja el cuerpo en los tres registros y el cuerpo como trama donde el síntoma hace escritura, explicitando qué se entiende como feroz y ferocidad, la diferencia entre estos conceptos y qué se entiende por estrago. Se desarrolla el goce de Niobe, Fedra, Electra, Medea, Antígona e Ifigenia, mujeres de los relatos de las tragedias griegas elegidas, entendiendo que la mortificación de sus cuerpos o el vínculo con su partenaire son efectos de lo feroz de la estructura. Se trabaja sobre la instancia psíquica del superyó y cómo se emparenta con el concepto de goce que trabaja Lacan en sus Seminarios. Metodológicamente, se trata de un estudio de diseño cualitativo de corte exploratorio, que pretende construir una articulación entre teoría y clínica dentro del campo del psicoanálisis. Fil: Bianchini, María Silvina. Universidad Nacional de La Matanza; Argentina.

Published
2018

44. Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.

Author

Morales DR, Ostropolets A, Lai L, Sena A, Duvall S, Suchard M, Verhamme K, Rjinbeek P, Posada J, Ahmed W, Alshammary T, Alghoul H, Alser O, Areia C, Blacketer C, Burn E, Casajust P, You SC, Dawoud D, Golozar A, Gong M, Jonnagaddala J, Lynch K, Matheny M, Minty E, Nyberg F, Uribe A, Recalde M, Reich C, Scheumie M, Shah K, Shah N, Schilling L, Vizcaya D, Zhang L, Hripcsak G, Ryan P, Prieto-Alhambra D, Durate-Salles T, and Kostka K

Subjects
Humans, United States epidemiology, SARS-CoV-2, Comorbidity, Hospitalization, COVID-19 epidemiology, Asthma epidemiology, Diabetes Mellitus epidemiology
Abstract

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma. Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ('diagnosed' and 'hospitalized') based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions. Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6-8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7-6.8) to 18.5% (95% CI 18.2-18.8) in the diagnosed cohort and 5.2% (95% CI 4.0-6.8) to 20.5% (95% CI 18.6-22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8-2.4) to 16.9% (95% CI 13.8-20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15-30% of hospitalized COVID-19 asthma patients. Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.[Box: see text]Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.2025392 .

Published
2023
Full Text
View/download PDF

45. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.

Author

Prieto-Alhambra D, Kostka K, Duarte-Salles T, Prats-Uribe A, Sena A, Pistillo A, Khalid S, Lai L, Golozar A, Alshammari TM, Dawoud D, Nyberg F, Wilcox A, Andryc A, Williams A, Ostropolets A, Areia C, Jung CY, Harle C, Reich C, Blacketer C, Morales D, Dorr DA, Burn E, Roel E, Tan EH, Minty E, DeFalco F, de Maeztu G, Lipori G, Alghoul H, Zhu H, Thomas J, Bian J, Park J, Roldán JM, Posada J, Banda JM, Horcajada JP, Kohler J, Shah K, Natarajan K, Lynch K, Liu L, Schilling L, Recalde M, Spotnitz M, Gong M, Matheny M, Valveny N, Weiskopf N, Shah N, Alser O, Casajust P, Park RW, Schuff R, Seager S, DuVall S, You SC, Song S, Fernández-Bertolín S, Fortin S, Magoc T, Falconer T, Subbian V, Huser V, Ahmed WU, Carter W, Guan Y, Galvan Y, He X, Rijnbeek P, Hripcsak G, Ryan P, and Suchard M

Abstract

Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD. Methods: We conducted a descriptive cohort study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11 th June 2020 and are iteratively updated via GitHub [4]. Findings: We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19 , and 113,627 hospitalized with COVID-19 requiring intensive services . All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts, and are available in an interactive website: https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Interpretation: CHARYBDIS findings provide benchmarks that contribute to our understanding of COVID-19 progression, management and evolution over time. This can enable timely assessment of real-world outcomes of preventative and therapeutic options as they are introduced in clinical practice.

Published
2021
Full Text
View/download PDF

46. Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States.

Author

Burn E, Sena AG, Prats-Uribe A, Spotnitz M, DuVall S, Lynch KE, Matheny ME, Nyberg F, Ahmed WU, Alser O, Alghoul H, Alshammari T, Zhang L, Casajust P, Areia C, Shah K, Reich C, Blacketer C, Andryc A, Fortin S, Natarajan K, Gong M, Golozar A, Morales D, Rijnbeek P, Subbian V, Roel E, Recalde M, Lane JCE, Vizcaya D, Posada JD, Shah NH, Jonnagaddala J, Lai LYH, Avilés-Jurado FX, Hripcsak G, Suchard MA, Ranzani OT, Ryan P, Prieto-Alhambra D, Kostka K, and Duarte-Salles T

Abstract

Objective: To estimate the proportion of patients hospitalized with COVID-19 who undergo dialysis, tracheostomy, and extracorporeal membrane oxygenation (ECMO)., Design: A network cohort study., Setting: Seven databases from the United States containing routinely-collected patient data: HealthVerity, Premier, IQVIA Hospital CDM, IQVIA Open Claims, Optum EHR, Optum SES, and VA-OMOP., Patients: Patients hospitalized with a clinical diagnosis or a positive test result for COVID-19., Interventions: Dialysis, tracheostomy, and ECMO., Measurements and Main Results: 842,928 patients hospitalized with COVID-19 were included (22,887 from HealthVerity, 77,853 from IQVIA Hospital CDM, 533,997 from IQVIA Open Claims, 36,717 from Optum EHR, 4,336 from OPTUM SES, 156,187 from Premier, and 10,951 from VA-OMOP). Across the six databases, 35,192 (4.17% [95% CI: 4.13% to 4.22%]) patients received dialysis, 6,950 (0.82% [0.81% to 0.84%]) had a tracheostomy, and 1,568 (0.19% [95% CI: 0.18% to 0.20%]) patients underwent ECMO over the 30 days following hospitalization. Use of ECMO was more common among patients who were younger, male, and with fewer comorbidities. Tracheostomy was broadly used for a similar proportion of patients regardless of age, sex, or comorbidity. While dialysis was generally used for a similar proportion among younger and older patients, it was more frequent among male patients and among those with chronic kidney disease., Conclusion: Use of dialysis among those hospitalized with COVID-19 is high at around 4%. Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial., Competing Interests: Competing interests All authors have completed the ICMJE uniform disclosure form, with the following declarations made: AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. AS is a full time employee of Janssen and shareholder of Johnson & Johnson. SDV reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., , grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research outside the submitted work. MEM has nothing to disclose. CR is an employee of IQVIA. CB reports other from Janssen, Research and Development, outside the submitted work; and full time employee of Janssen R&D and Johnson & Johnson shareholder. AA reports other from Janssen, Research and Development, outside the submitted work; and full time employee of Janssen R&D and Johnson & Johnson shareholder. SF reports other from Janssen, outside the submitted work. AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work. She is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. DM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from Tenovus, grants from National Institute of Health Research (NIHR), outside the submitted work. PR reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study. VS reports grants from National Science Foundation, grants from State of Arizona; Arizona Board of Regents, grants from Agency for Healthcare Research and Quality, outside the submitted work. DV reports personal fees from Bayer, outside the submitted work; and he is a full-time employee at a pharmaceutical company. GH reports grants from US NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work. MAS reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study .PR reports and is employee of Janssen Research and Development and shareholder of Johnson & Johnson. DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants. KK reports she is an employee of IQVIA. All other authors declare no competing interests.

Published
2021
Full Text
View/download PDF

47. Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study.

Author

Duarte-Salles T, Vizcaya D, Pistillo A, Casajust P, Sena AG, Lai LYH, Prats-Uribe A, Ahmed WU, Alshammari TM, Alghoul H, Alser O, Burn E, You SC, Areia C, Blacketer C, DuVall S, Falconer T, Fernandez-Bertolin S, Fortin S, Golozar A, Gong M, Tan EH, Huser V, Iveli P, Morales DR, Nyberg F, Posada JD, Recalde M, Roel E, Schilling LM, Shah NH, Shah K, Suchard MA, Zhang L, Zhang Y, Williams AE, Reich CG, Hripcsak G, Rijnbeek P, Ryan P, Kostka K, and Prieto-Alhambra D

Abstract

Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents diagnosed with previous seasonal influenza. Design International network cohort. Setting Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. Participants Diagnosed and/or hospitalized children/adolescents with COVID-19 at age <18 between January and June 2020; diagnosed with influenza in 2017-2018. Main outcome measures Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and death. Results A total of 55,270 children/adolescents diagnosed and 3,693 hospitalized with COVID-19 and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were all more common among those hospitalized vs diagnosed with COVID-19. The most common COVID-19 symptom was fever. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital treatments for COVID-19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia, ARDS, and MIS-C were more frequent in COVID-19 than influenza. Conclusions Despite negligible fatality, complications including pneumonia, ARDS and MIS-C were more frequent in children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal symptoms could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19.

Published
2020
Full Text
View/download PDF

48. Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States.

Author

Golozar A, Lai LY, Sena AG, Vizcaya D, Schilling LM, Huser V, Nyberg F, Duvall SL, Morales DR, Alshammari TM, Abedtash H, Ahmed WU, Alser O, Alghoul H, Zhang Y, Gong M, Guan Y, Areia C, Jonnagaddala J, Shah K, Lane JCE, Prats-Uribe A, Posada JD, Shah NH, Subbian V, Zhang L, Abrahão MTF, Rijnbeek PR, You SC, Casajust P, Roel E, Recalde M, Fernández-Bertolín S, Andryc A, Thomas JA, Wilcox AB, Fortin S, Blacketer C, DeFalco F, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Hripcsak G, Suchard M, Lynch KE, Matheny ME, Williams A, Reich C, Duarte-Salles T, Kostka K, Ryan PB, and Prieto-Alhambra D

Abstract

Early identification of symptoms and comorbidities most predictive of COVID-19 is critical to identify infection, guide policies to effectively contain the pandemic, and improve health systems' response. Here, we characterised socio-demographics and comorbidity in 3,316,107persons tested and 219,072 persons tested positive for SARS-CoV-2 since January 2020, and their key health outcomes in the month following the first positive test. Routine care data from primary care electronic health records (EHR) from Spain, hospital EHR from the United States (US), and claims data from South Korea and the US were used. The majority of study participants were women aged 18-65 years old. Positive/tested ratio varied greatly geographically (2.2:100 to 31.2:100) and over time (from 50:100 in February-April to 6.8:100 in May-June). Fever, cough and dyspnoea were the most common symptoms at presentation. Between 4%-38% required admission and 1-10.5% died within a month from their first positive test. Observed disparity in testing practices led to variable baseline characteristics and outcomes, both nationally (US) and internationally. Our findings highlight the importance of large scale characterization of COVID-19 international cohorts to inform planning and resource allocation including testing as countries face a second wave., Competing Interests: COMPETING INTEREST STATEMENT All authors have completed the ICMJE uniform disclosure form, with the following declarations made: DPA reports grants from Amgen, grants and other from UCB Biopharma, grants from Johnson and Johnson, outside the submitted work. DM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), and Tenovus outside the submitted work. SCY reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work; and she is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Dr. Lane reports grants from Versus Arthritis, grants from Medical Research Council, outside the submitted work. MS reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study. HA reports personal fees from Eli Lilly and Company, outside the submitted work. AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. AS is a full-time employee of Janssen and shareholder of Johnson & Johnson. FD reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. KK reports she is an employee of IQVIA. CR reports he is an employee of IQVIA. FN was an employee of AstraZeneca until 2019 and holds some AstraZeneca shares. SF is an employee of Janssen Research and Development, a subsidiary of Johnson and Johnson. VS reports grant funding from the National Science Foundation, Agency for Healthcare Research and Quality, and the Arizona Board of Regents outside of the submitted work. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. PR reports and is employee of Janssen Research and Development and shareholder of Johnson & Johnson. No other relationships or activities that could appear to have influenced the submitted work.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results